Claims
- 1. A method of treating a contact lens wherein a lens is contacted with an effective amount of bendazac, 5-hydroxy-bendazac or of a salt thereof with an inorganic or organic physiologically acceptable base, said lens being in the eye and said contact occurring inside the eye.
- 2. A method of inhibiting protein sedimentation from lacrimal fluid on a contact lens and neutralizing irritative effect of existing protein sediments without substantially affecting mucus secretion by mucous membranes of the contact lens wearer wherein said lens is contacted with an effective amount of a composition comprising bendazac, 5-hydroxy-bendazac, or a salt thereof with an inorganic or organic physiologically acceptable base, and a physiologically acceptable carrier, said contact occurring after insertion into the eye.
- 3. The method, as in claim 2 wherein the contact lens is a soft contact lens.
- 4. The method, as in claim 2 wherein the effective amount of bendazac or 5-hydroxy-bendazac is 0.05-2% or the corresponding amount of the salt thereof.
- 5. The method, as in claim 2 wherein the physiologically acceptable base is selected from the group consisting of sodium, potassium, aliphatic amines and basic aminoacids.
- 6. The method, as in claim 2 wherein the physiologically acceptable carrier is water.
- 7. The method, as in claim 2 wherein the composition further comprises surfactants or enzymes.
- 8. The method, as in claim 2 wherein the composition further comprises one or more of the group consisting of preservatives, salts for regulating osmotic pressure, antiseptics disinfectants, antioxidants and buffers.
- 9. The method, as in claim 7 wherein the enzymes comprises papain.
- 10. The method, as in claim 7 wherein the surfactant comprises octylphenyoxyoctanol.
- 11. The method, as in claim 8 wherein the disinfectant comprises chloxhexidine gluconate.
- 12. The method, as in claim 2 wherein the composition comprises, in 100 mls of distilled water
- ______________________________________Bendazac lysinate 0.4 gHydroxy ethyl cellulose 0.4 gPolyvinyl alcohol 1.4 gThymerosal 0.004 gSodium edetate 0.2 gSodium chloride 0.75 gBoric acid or borax to pH 7.4.______________________________________
- 13. The method, as in claim 2, wherein said contact occurs after insertion into the eye of an individual who does not suffer from cataract.
- 14. The method, as in claim 2, wherein said contact occurs after insertion into the eye of an individual who has not been diagnosed as suffering from cataract.
Priority Claims (1)
Number |
Date |
Country |
Kind |
21384 A/86 |
Aug 1986 |
ITX |
|
Parent Case Info
This is a divisional of copending application Ser. No. 07/296,275 filed on Jan. 11, 1989 now U.S. Pat. No. 4,895,670 which is a continuation application of Ser. No.: 07/077,620 filed on July 24, 1987 (now abandoned).
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4451477 |
Silvestrini |
May 1984 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
2151039A |
Jul 1985 |
GBX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
296275 |
Jan 1989 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
77620 |
Jul 1987 |
|